Cure8 research brief
Single-cell and spatial multi-omics help explain why many patients do not respond to current biologics and JAK inhibitors and point toward molecular and cellular biomarkers that could one day guide more precise treatment choices.
Researchers studying IBD mechanisms or biomarkers; clinicians and gastroenterologists managing patients who fail biologics or JAK inhibitors; patients on biologic or small-molecule therapy interested in precision-treatment research.
This article synthesizes single-cell and spatial multi-omics studies across drugs that target TNF, integrins, IL-12/23, and JAK pathways.
The authors organize findings into three interacting "cellular hallmarks": immune dysregulation, stromal remodeling, and epithelial reprogramming, and argue that effective treatment may require remodeling multicellular communication networks rather than only blocking a single molecule.
The review describes mechanisms linked to treatment resistance such as activation of bypass pathways, enrichment of pathogenic cell subsets, and drug-induced reprogramming.
It also notes emerging predictive approaches that integrate multicellular modules and dynamic gene-expression signatures to stratify patients, but emphasizes that these require functional validation and prospective clinical testing before clinical use.
The article is a review (abstract-level summary provided). Findings summarize existing single-cell and spatial studies rather than reporting new clinical trial outcomes. Proposed predictive tools and mechanistic candidates need functional validation and prospective clinical evaluation.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Interdisciplinary Research Support Program of Huazhong University of Science and Technology - 2025JCYJ069; Natural Science Foundation of Hubei Province - 2023AFD044; National Natural Science Foundation of China - 82270559; National Natural Science Foundation of China - 82070572
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If you or someone you care for is not responding to anti‑TNF drugs for ulcerative colitis, this review explains biological reasons why that may happen and points toward research directions that could lead to better tests...
This narrative review surveys novel biomarkers and therapeutic strategies for adult IBD, topics that could affect diagnosis, monitoring, and future treatment options for people with Crohn's disease or ulcerative colitis.
This matters because identifying microbiome patterns linked to infliximab response could help predict which children with IBD are more likely to benefit from the drug and guide personalized treatment decisions in the...
